Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]
One of the unsettled debates in our advanced prostate cancer world surrounds the issue of continuous vs. intermittent hormone therapy (IHT). Traditionally, hormone therapy was continuous, or once you started you never stopped the treatment. As many of us know, hormone therapy is notorious for damaging the quality of life. Hot flashes, loss of libido, [...]
That is the big question I am dealing with this week. I have been so pleased with my recent success with lowering my PSA, but the last test has reversed the trend. My PSA has shown a drastic rise. It went from just under .60 to almost 2.0 within a two week period! As we [...]
A small phase III, randomized, double blind, placebo controlled trial of Gabapentin which looked at the Management of hot flashes in men on a hormone blockade (ADT) was recently completed and published in the March 2009 journal of the Ann of Oncology. One of the most common and bothersome side effects of a hormone blockade [...]
A small study of 145 men with asymptomatic metastatic hormone-refractory prostate cancer (HRPC) was conducted to determine the benefit of starting early chemotherapy with docetaxel. Collected data were analyzed from these subjects who were treated with chemotherapy between February 2000 and June 2002 in one French center. The men were categorized into three groups according [...]